Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Debora Fumagalli

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2016
Genomic Characterization of Primary Invasive Lobular Breast CancerChristine Desmedt, Gabriele Zoppoli, Gunes Gundem, et al.
The Journal of Pathology|April 9, 2015
Uncovering the genomic heterogeneity of multifocal breast cancerChristine Desmedt, Debora Fumagalli, Elisabetta Pietri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2021
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-UpMartine Piccart, Marion Procter, Debora Fumagalli, et al.
European Journal of Cancer (Oxford, England : 1990)|February 16, 2022
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrantLuca Malorni, Svitlana Tyekucheva, Florentine S Hilbers, et al.
European Journal of Cancer (Oxford, England : 1990)|March 25, 2021
Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)Alvaro Moreno-Aspitia, Eileen M Holmes, Christian Jackisch, et al.
Journal of the National Cancer Institute|November 23, 2013
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31Katherine L Pogue-Geile, Chungyeul Kim, Jong-Hyeon Jeong, et al.
The Lancet. Oncology|March 15, 2021
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by ageMartine Piccart, Laura J van 't Veer, Coralie Poncet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 23, 2018
Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient DataDimitrios Zardavas, Luc Te Marvelde, Roger L Milne, et al.
The New England Journal of Medicine|June 3, 2021
Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast CancerAndrew N J Tutt, Judy E Garber, Bella Kaufman, et al.
The Lancet. Oncology|January 18, 2021
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 studyErica L Mayer, Amylou C Dueck, Miguel Martin, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2016
Genomic Characterization of Primary Invasive Lobular Breast CancerChristine Desmedt, Gabriele Zoppoli, Gunes Gundem, et al.
The Journal of Pathology|April 9, 2015
Uncovering the genomic heterogeneity of multifocal breast cancerChristine Desmedt, Debora Fumagalli, Elisabetta Pietri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2021
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-UpMartine Piccart, Marion Procter, Debora Fumagalli, et al.
European Journal of Cancer (Oxford, England : 1990)|February 16, 2022
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrantLuca Malorni, Svitlana Tyekucheva, Florentine S Hilbers, et al.
European Journal of Cancer (Oxford, England : 1990)|March 25, 2021
Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)Alvaro Moreno-Aspitia, Eileen M Holmes, Christian Jackisch, et al.
Journal of the National Cancer Institute|November 23, 2013
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31Katherine L Pogue-Geile, Chungyeul Kim, Jong-Hyeon Jeong, et al.
The Lancet. Oncology|March 15, 2021
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by ageMartine Piccart, Laura J van 't Veer, Coralie Poncet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 23, 2018
Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient DataDimitrios Zardavas, Luc Te Marvelde, Roger L Milne, et al.
The New England Journal of Medicine|June 3, 2021
Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast CancerAndrew N J Tutt, Judy E Garber, Bella Kaufman, et al.
The Lancet. Oncology|January 18, 2021
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 studyErica L Mayer, Amylou C Dueck, Miguel Martin, et al.
Pageof 7